351P - Real-world study of herombopag in primary prevention and treatment of chemotherapy-induced thrombocytopenia (CIT) in advanced lung cancer

Background

As is known to all, CIT generally begins 7 days after chemotherapy and reaches its lowest point at 10 days. This study investigated effectiveness and safety of primary prevention and treatment in patients with CIT after administration of Herombopag(a TPO-RA) in a real-world setting. The NCCN guidelines recommend that TPO-RA be considered in treating CIT. However, there is no clinical data on using Herombopag in primary prevention and treatment of CIT in advanced lung cancer.

Methods

The study enrolled 34 patients received treatment protocol including platinum antineoplastic agent, high risky for CIT. 12 patients were in the treatment group, and 22 patients were in the prevention group. All the patients received herombopag(7.5mg/d) after chemothepay. Blood platelet counts was measured at baseline(D1)and 10 days later(D10). The primary endpoint was incidence of thrombocytopenia at D10 in two groups. The tocxicity was determined according to CTCAE 4.0.

Results

The patients were enrolled From Jan. 2022 to Apr. 2022. The average age was 63 years old. The PS score of 32 patients were 1 and 2 patients were 2. All the patients showed best response speed. In the treatment group, all the patients especially Pt3 and Pt7 platelet counts under 25×10⁹/L were back to normal condition at D10 with the treatment of herombopag. In the prevention group, there was no one patient had thrombocytopenia or hyperplatelet at D10 with the treatment of herombopag. The toxicities associated with this protocols were manageable. Only 1 patient was 3/4-grade proteinuria and 3 patients was 3/4-grade elevated alaninetransaminase.

Conclusions

Herombopag exhibits superior activity and generally manageable toxicities for prevention and treatment of CIT in advanced lung cancer. It may provide a new and effective therapy strategy for them, but large sample and additional clinical trials are also needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.